Genetic polymorphisms of FAS and FASL (CD95/CD95L) genes in cervical carcinogenesis: An analysis of haplotype and gene–gene interaction

Lai, Hung Cheng; Lin, Weihong; Lin, Yu-Shen; Chang, Cheng‐Chang; Mu, Yu; Chen, Chia Chi; Chu, Tang-Yuan

doi:10.1016/j.ygyno.2005.05.010

Cited by 70 publications

(70 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The 318 cases consisted of 143 patients with high-grade squamous intraepithelial lesions and 175 patients with invasive squamous cell carcinoma of the cervix. 51 In our study, we examined mostly carcinoma in situ cases and observe a C allele frequency of 70% in the cases and 71% in the controls. There are several possible explanations for the discrepancy in results between our study and that by Sun et al The difference may reflect population structure; an SNP that is relevant in the Chinese population may not necessarily be relevant in the Swedish population.…”

Section: Discussionmentioning

confidence: 77%

Variants of chemokine receptor 2 and interleukin 4 receptor, but not interleukin 10 or Fas ligand, increase risk of cervical cancer

Ivansson

Gustavsson

Magnusson

et al. 2007

Intl Journal of Cancer

View full text Add to dashboard Cite

Cervical cancer is caused by persistent infection of oncogenic human papillomavirus (HPV). Most infected women clear the virus without developing cervical lesions and it is likely that immunological host factors affect susceptibility to cervical cancer. The impact of the human leukocyte antigen (HLA) locus on the risk of cervical cancer is established and several other genes involved in immunological pathways have been suggested as biologically plausible candidates. The aim of this study was to examine the potential role of polymorphisms in 4 candidate genes by analysis of 1,306 familial cervical cancer cases and 288 controls. The following genes and polymorphisms were studied: Chemokine receptor 2 (CCR-2) V64I; Interleukin 4 receptor a (IL-4R) I75V, S503P and Q576R; Interleukin 10 (IL-10) 2592; and Fas ligand (FasL) 2844. The CCR-2 64I variant was associated with decreased risk of cervical cancer; homozygote carriers of the 64I variant had an odds ratio of 0.31 (0.12-0.77). This association was detected in both carriers and noncarriers of the HLA DQB1*0602 cervical cancer risk allele. The IL-4R 75V variant was associated with increased risk of cervical tumors, cases homozygote for 75V had an odds ratio of 1.91 (1.27-2.86) with a tendency that the association was stronger in noncarriers of the DQB1*0602 allele. We did not find any association for IL-10 2592, or FasL 2844, previously reported to be associated with cervical cancer in the Dutch and Chinese populations, respectively. ' 2007 Wiley-Liss, Inc.

show abstract

Section: Discussionmentioning

confidence: 77%

Variants of chemokine receptor 2 and interleukin 4 receptor, but not interleukin 10 or Fas ligand, increase risk of cervical cancer

Ivansson

Gustavsson

Magnusson

et al. 2007

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…Based on a literature search and selection, a total of 10 publications (11)(12)(13)(14)(15)(16)(17)(18)(19)22) comparing the FAS/ FASL polymorphism and cervical cancer susceptibility were identified. Among these studies, 1 study was in Chinese (22) and 1 study contained data on two different ethnicities (18).…”

Section: Resultsmentioning

confidence: 99%

“…Although evidence of an association between FAS/FASL polymorphisms and cervical cancer risk has been reported, the findings remain controversial (11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21)(22). Therefore, we performed a meta-analysis of all published studies on the association between the FAS/FASL polymorphisms and cervical cancer.…”

Section: Introductionmentioning

confidence: 99%

Lack of association between the FAS/FASL polymorphisms and cervical cancer risk: A meta-analysis

Pan

2013

Biomedical Reports

View full text Add to dashboard Cite

Abstract. FAS/FASL gene promoter polymorphisms are associated with cervical cancer risk, however, results from previous studies have been conflicting. To obtain a more precise estimation of the association between these polymorphisms and cancer risk, a meta-analysis was performed. All eligible studies up to November 1st, 2012, concerning FAS-670 A/G, FAS-1377 G/A and FASL-844 T/C polymorphisms and cervical cancer risk, were collected from the following electronic databases: PubMed, Excerpta Medica Database and Chinese Biomedical Literature Database. The odds ratio (OR) and 95% confidence interval (95% CI) were used to assess the strength of the association via the additive, codominant, dominant and recessive models. In total, 10 publications with 11 case-control studies (10 on FAS-670 A/G, 5 on FAS-1377 G/A and 6 on FASL-844 T/C polymorphisms) were included in this meta-analysis. No association between FAS-670 A/G, FAS-1377 G/A and FASL-844 T/C polymorphisms and cervical cancer susceptibility for all the genetic models was identified. Following stratification of the studies by ethnicity or source of controls, similar results were obtained. In conclusion, our findings showed that the FAS-670 A/G, FAS-1377 G/A and FASL-844 T/C polymorphisms are not associated with cervical cancer risk. Future studies with larger sample sizes are required to further evaluate these associations.

show abstract

“…A significantly associated risk was found for FAS À670 A/G polymorphism in bladder, 13 cervical cancer, 11,16,22 cutaneous malignant melanoma, 12 esophageal and head and neck squamous cell carcinoma, 15,21 lung and nasopharyngeal cancer. 9,17,20 We analyzed the frequency of FAS genotypes in the normal control population.…”

Section: Discussionmentioning

confidence: 96%

“…7,8 In addition, polymorphisms in the FAS gene and perhaps also in the FASL gene that impair apoptotic signal transduction are associated with a high risk of cancer in various models. [9][10][11][12][13][14][15][16][17][18][19][20][21][22] Thus, the FAS/FASL system appears to have a role in the development and progression of cancer.…”

Section: Introductionmentioning

confidence: 99%

Association between FAS polymorphism and prostate cancer development

Lima

Morais

Lobo

et al. 2007

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

The role of FAS polymorphisms in prostate cancer has not been studied. Using the PCR-based restriction fragment-length polymorphism methodology, we evaluated FAS gene locus À670 genotypes in DNA from 904 men: 657 prostate cancer patients and 247 healthy controls. We found that carriers of AG or GG genotypes have a statistically significant protection (odds ratio (OR) ¼ 0.30; confidence interval (CI): 0.20-0.44 and OR ¼ 0.22; CI: 0.12-0.74, respectively) for disease with extra-capsular invasion. Taken together, a 72% protection was found for G allele carriers (OR ¼ 0.28; CI: 0.19-0.41). Fas exist as membrane-bound and soluble forms and with opposite roles. They derive from the same gene by alternative splicing. Membrane Fas receptors trigger apoptosis whereas, on the other hand, soluble Fas (sFas) bind to Fas ligand antagonizing Fas-Fas ligand apoptotic pathway. Our results suggest that G allele may reduce sFas levels preventing the apoptotic inhibition caused by the soluble form.

show abstract

Genetic polymorphisms of FAS and FASL (CD95/CD95L) genes in cervical carcinogenesis: An analysis of haplotype and gene–gene interaction

Cited by 70 publications

References 44 publications

Variants of chemokine receptor 2 and interleukin 4 receptor, but not interleukin 10 or Fas ligand, increase risk of cervical cancer

Variants of chemokine receptor 2 and interleukin 4 receptor, but not interleukin 10 or Fas ligand, increase risk of cervical cancer

Lack of association between the FAS/FASL polymorphisms and cervical cancer risk: A meta-analysis

Association between FAS polymorphism and prostate cancer development

Contact Info

Product

Resources

About